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Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) are the
cornerstone of therapy for relief of pain and inflammation
in patients with acute and chronic musculoskeletal dis-
eases, particularly osteoarthritis (OA) and rheumatoid
arthritis (RA). The use of these drugs is limited, however,
primarily by their toxicity. Nonselective NSAIDs (i.e. those
that inhibit both cyclooxygenase [COX]-1 and COX-2
[see below]) are associated with an increased risk for
serious upper gastrointestinal (GI) complications, includ-
ing perforation, symptomatic ulcers and bleeding (PUBs);
nephrotoxicity, including edema, hypertension, and acute
renal insufficiency; and congestive heart failure [1,2].
After the discovery in the late 1980s of a second isoform
of cyclooxygenase, it was proposed that the COX-1 isoen-
zyme is expressed constitutively and the COX-2 isoen-
zyme is induced at sites of inflammation; hence,
prostaglandins synthesized by COX-1 were suggested to
be responsible for ‘housekeeping’ functions in the GI tract,
kidney, and platelet, while those synthesized by COX-2
were responsible for pain and signs of inflammation in
patients with arthritis. This led to the development of the
‘COX-2 hypothesis’: that NSAIDs that inhibit the COX-2
but not the COX-1 enzyme at therapeutic plasma concen-
trations would have the beneficial anti-inflammatory and
analgesic effects but not the gastrointestinal or renal toxic-
ity of nonselective NSAIDs [3]. The hypothesis was
revised after the discovery that COX-2 was constitutively
expressed in the kidney [4], to include protection only from
GI complications, including PUBs.
Efficacy and GI safety of COX-2 selective
inhibitors
Four COX-2 selective inhibitors have been approved and
are marketed for use in the treatment of patients with OA
and RA in some European, North American, and Latin
American countries (Table 1); a fifth compound, lumira-
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Abstract
Cyclooxygenase (COX)-2 selective inhibitors have been shown to have comparable efficacy to
nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of patients with
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OA and RA not taking low-dose aspirin have fewer symptomatic and complicated upper GI events
when treated with COX-2 selective inhibitors than with nonselective NSAIDs. When used in
recommended dosages, there is no convincing evidence that patients treated with COX-2 selective
inhibitors have an increased incidence of cardiovascular thrombotic events, including non-fatal
myocardial infarction, than patients treated with either placebo or nonselective NSAIDs other than
naproxen. Co-therapy with low-dose aspirin is recommended in patients with OA and RA at increased
risk for cardiovascular events; the need for gastroprotective therapy in such patients is controversial.
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coxib (Prexige [Novartis, Basel. Switzerland]), is currently in
phase III development. Schnitzer and Hochberg reviewed
the phase II and III randomized, controlled trials of these
agents and concluded that all were more efficacious than
placebo and all had similar efficacy compared with nonse-
lective NSAIDs when used in therapeutic doses [5]. The
single exception was one study that showed that etoricoxib
at 90mg per day was more efficacious than naproxen at
500mg twice daily in patients with RA [6]. Thus, the first
part of the COX-2 hypothesis is satisfied.
Acceptance of the second part of the COX-2 hypothesis
requires the demonstration that patients treated with
COX-2 selective inhibitors have fewer clinically important
upper GI complications, especially complicated PUBs,
than patients treated with nonselective NSAIDs. Two large
outcome studies were conducted to test this hypothesis:
the Vioxx Gastrointestinal Outcomes Research (VIGOR)
Trial [7] and the Celecoxib Long-term Arthritis Safety Study
(CLASS) [8]. Updated information on both of these studies
was reported to the US Food and Drug Administration
(FDA) Arthritis Advisory Committee in February 2001
(www.fda.gov/ohrms/dockets/ac/cder01.htm#Arthritis).
In the VIGOR trial, patients who received rofecoxib (50mg
per day) had significantly lower rates of both clinically
important upper GI events (PUBs, the primary outcome)
and complicated PUBs (the key secondary outcome) than
patients treated with the nonselective NSAID naproxen at
a dose of 500mg twice a day: the respective relative risks
(95% confidence intervals) were 0.46 (0.33, 0.64) and
0.43 (0.24, 0.78) [7].
In the CLASS, the rates of complicated PUBs (the primary
outcome) were not significantly different between patients
treated with celecoxib (400mg twice a day) and the
pooled NSAID comparators, diclofenac (75mg twice a
day) and ibuprofen (800mg three times a day). Patients
treated with celecoxib did, however, have a significantly
lower incidence of the secondary outcome, symptomatic
and complicated ulcers (PUBs), than did patients taking
the nonselective NSAIDs. In the preplanned analyses
comparing individual NSAIDs, the differences between
celecoxib and ibuprofen were significant while those
between celecoxib and diclofenac were not. In a post hoc
analysis limited to patients not taking low-dose aspirin, the
rate of both the primary and secondary outcomes was sig-
nificantly lower in patients receiving celecoxib compared
with patients receiving ibuprofen but not compared with
patients receiving diclofenac.
Differences between the designs of these studies, particu-
larly patient inclusion and exclusion criteria, choice of
comparator NSAIDs, choice of primary and secondary out-
comes, and underlying assumptions about reductions in
risks for the primary outcome that were used to estimate
sample size, have been noted by several authors to possi-
bly explain the disparate results [9–11]. In addition to
highlighting the potential flaws in the design of CLASS
that might have explained the lack of achieving the primary
outcome, Juni and colleagues also questioned the validity
of the results [12]. A subsequent meta-analysis of nine
randomized, controlled trials of celecoxib lasting 12 weeks
or longer confirmed the GI safety of celecoxib compared
with nonselective NSAIDs [13]; however, this meta-analy-
sis included only the 6-month data published by Silver-
stein and colleagues [8] and did not include the entire
data presented at the FDA hearing. From my own review
of the data [9], I concluded that the COX-2 selective
inhibitors celecoxib and rofecoxib did fulfil the ‘revised’
COX-2 hypothesis.
Does this GI safety advantage extend to the newer COX-2
selective inhibitors? Data from a meta-analysis of phase II
and III studies of etoricoxib also demonstrate a signifi-
cantly lower rate of PUBs in patients treated with this
COX-2 selective inhibitor than in those treated with nons-
elective NSAID comparators [14]. A similar meta-analysis
including studies of valdecoxib is anticipated. Lumiracoxib
is currently being studied in a large outcome study
designed to enroll 18,000 patients.
Unresolved issues
On the basis of these data, one should recommend that
COX-2 selective inhibitors be used in patients with
arthropathies, especially OA and RA, who are at increased
risk for upper GI complications from nonselective NSAIDs
[15]. Established risk factors for the development of PUBs
in patients treated with nonselective NSAIDs include age
≥65, a history of peptic ulcer disease or of upper GI
bleeding, concomitant use of oral corticosteroids or anti-
coagulants, and, possibly, smoking and alcohol consump-
tion [16–18]. Fendrick stated that the “unrestricted
access to COX-2 selective inhibitors could be both clini-
cally and economically advantageous because of the high
likelihood of …safety benefits from coxibs” and suggested
that “COX-2 selective inhibitors should be offered as first-
line therapy to these high-risk patients” [19].
Table 1
COX-2 selective inhibitors currently marketed in some
European, North American, and Latin American countries
Generic Proprietary
name name Manufacturer
celecoxib Celebrex Pharmacia Corporation and Pfizer, Inc
etoricoxib Arcoxia Merck & Co, Inc
rofecoxib Vioxx Merck & Co, Inc
valdecoxib Bextra Pharmacia Corporation and Pfizer, Inc30
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Unfortunately, the reality of the situation in the autumn of
2002 is not that simple. Two major questions remain
unanswered: 1) are COX-2 selective inhibitors associated
with an increased risk of cardiovascular thrombotic
events? and 2) does concomitant therapy with low-dose
aspirin, used for cardioprotection, eliminate the safety
benefit of COX-2 selective inhibitors in comparison with
nonselective NSAIDs?
The first question is based on the surprising finding in the
VIGOR trial that patients who received rofecoxib had
higher risk of cardiovascular thrombotic events, particu-
larly nonfatal myocardial infarction, than patients who
received naproxen [7]. Fitzgerald and Patrono proposed
three hypotheses to explain these results: an antithrom-
botic effect of naproxen, a prothrombotic effect of rofe-
coxib, and the ‘play of chance’ [20]. Five observational
epidemiologic studies published in the past 2 years exam-
ined the effect of NSAIDs, particularly naproxen, on the
risk of cardiovascular thrombotic events including myocar-
dial infarction; these studies were reviewed recently by
Strand and Hochberg [21]. The results of a majority of
these studies are consistent with a modest protective
effect of naproxen on the development of nonfatal myocar-
dial infarction; indeed, Dalen, in his editorial accompanying
the three papers published in the Archives of Internal
Medicine, concluded that the most likely explanation of the
results in the VIGOR trial was “that naproxen decreases
the incidence of acute myocardial infarction” [22]. Patrono
suggested that a combination of a protective effect of
naproxen and the “play of chance” operating in a short-
term study [median follow-up of 9 months] with small
numbers of events in a low-risk population [event rate
below 1% per year] explained the findings in the VIGOR
trial (Patrono C, Invited Lecture on 28 October 2002 at
annual meeting of American College of Rheumatology,
New Orleans, LA). Two meta-analyses have failed to
demonstrate an increased risk of cardiovascular throm-
botic events in patients receiving rofecoxib at doses
ranging from 12.5 to 50mg per day in comparison with
both placebo and nonselective NSAIDs other than
naproxen [23,24]. However, the dose of rofecoxib in the
VIGOR trial was double the highest FDA-approved dose
for chronic treatment in both OA and RA, and there were
small numbers of patients treated who received this dose
in the phase II and III OA and RA trials in which naproxen
was not used as a comparator. Ray recently published
results of a retrospective cohort study using data from the
Tennessee Medicaid database and reported that new
users of rofecoxib at doses greater than 25mg per day
had almost a twofold increased risk of serious cardiovas-
cular events in comparison with controls not receiving
NSAIDs, while users of rofecoxib at doses of 25mg per
day or less had no increased risk of such events [25]. The
results of a meta-analysis of data from 15 controlled trials
of celecoxib involving over 30,000 patients failed to
demonstrate an increased risk of cardiovascular throm-
botic events in patients who received celecoxib compared
with those who received placebo or nonselective NSAIDs
including naproxen [26]. Similarly, the results of an analy-
sis of pooled data from four randomized, controlled trials
of valdecoxib in over 3000 patients with RA failed to
demonstrate an increased risk of cardiovascular throm-
botic events [27].
Thus, it is unlikely that this increased risk is a class effect
of COX-2 selective inhibitors when used in therapeutic
doses. It seems prudent, however, not to use doses higher
than those recommended for chronic therapy – i.e. rofe-
coxib 12.5 or 25mg per day, celecoxib 200 or 400mg per
day, or valdecoxib 10 mg per day. Insufficient data are
available at present to make definitive statements about
the use of etoricoxib, other than to note that at recom-
mended doses of 60 or 90mg per day for chronic therapy
of OA and RA, respectively, there is no apparent
increased risk of cardiovascular thrombotic events in com-
parison with placebo and, in patients with RA, there is a
reduced risk of such events in patients randomized to
naproxen, the comparator NSAID in the phase III trials
(Arcoxia Product Information, Merck & Co, Inc, White-
house Station, NJ, USA).
Use with low-dose aspirin
It is known that COX-2 selective inhibitors do not inhibit
platelet aggregation, and hence low-dose aspirin should
be used when appropriate for cardioprotection [15]. The
indications for use of low-dose aspirin for primary and sec-
ondary prevention of cardiovascular disease are beyond
the scope of this commentary. Nonetheless, if low-dose
aspirin is used in conjunction with a COX-2 selective
inhibitor in a patient at increased risk for both upper GI
complications from nonselective NSAIDs and cardio-
vascular thrombotic events, the safety of this combination
needs to be determined. There are at present insufficient
data to draw conclusions about this question. In CLASS,
the annualized incidence, based on the 6-month data, of
complicated and complicated plus symptomatic ulcers in
patients taking low-dose aspirin was, respectively, 2.0 and
4.7 per 100 for patients taking celecoxib, and 2.1 and
6.0 per 100 for patients taking comparator NSAIDs [8]. In
addition, patients taking celecoxib and low-dose aspirin
had a fourfold higher rate of complicated ulcers than
patients taking celecoxib alone [8]. These data suggest
that low-dose aspirin modified the effect of celecoxib in
comparison with nonselective NSAIDs. Comparable data
are not available for rofecoxib, as patients taking low-dose
aspirin were excluded by the protocol from participation in
the VIGOR trial. Hence, it is unclear whether concomitant
therapy with low-dose aspirin completely blocks the bene-
ficial effects of a COX-2 selective inhibitor. It is prudent,
therefore, to consider concomitant therapy with a gastro-
protective agent such as a proton pump inhibitor or miso-31
prostil in patients who must receive both low-dose aspirin
and a coxib if their risk of upper GI events is of sufficient
magnitude. There is at present no evidence, based on
results of experiments with rofecoxib, that COX-2 selec-
tive inhibitors interfere with the antiplatelet effects of low-
dose aspirin, as these inhibitors do not enter the channel
of the COX-1 enzyme to block the binding site of aspirin
to the serine residue in position 529 [28].
Conclusion
It is apparent as we enter 2003 that the study of COX-2
selective inhibitors will remain an exciting and active area
of basic and clinical research with an expected evolution
and revision of evidence-based recommendations. The
recent discovery of an alternative splice variant of COX-1
that is selectively inhibited by acetaminophen and potently
inhibited by some nonselective NSAIDs may provide
another pathway for development of additional agents for
treatment of patients with arthritis [29]. Further large out-
comes studies of COX-2 selective inhibitors in patients
with arthritis and as cancer chemopreventive agents may
produce additional informative data on the unresolved
issues discussed above.
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